A solid-phase technique for preparation of no-carrier-added technetium-99m radiopharmaceuticals: Application to the streptavidin/biotin system

被引:13
作者
Dunn-Dufault, R
Pollak, A
Fitzgerald, J
Thornback, JR
Ballinger, JR
机构
[1] Addenbrookes Hosp, Dept Nucl Med, Cambridge CB2 2QQ, England
[2] Univ Toronto, Fac Pharm, Toronto, ON, Canada
[3] Resolut Pharmaceut Inc, Mississauga, ON, Canada
关键词
technetium-99m; specific activity; receptor binding; streptavidin/biotin;
D O I
10.1016/S0969-8051(00)00156-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A high effective specific activity (HESA) formulation of a biotin containing Tc-99m ligand [RP488: dimethyl-Gly-Ser-Cys(Acm) Lys(Biotin)-Gly] conveniently prepared from solid phase was com pared to a typical low effective specific activity (LESA) solution formulation to demonstrate improved targeting to streptavidin in an in vitro assay and in an in vivo rat model. RP488 was coupled to a maleimide-functionalized polyethylene glycol resin via a thiol ether linkage and labeled with Tc-99m gluconate at room temperature, followed by elution of the HESA Tc-99m-RP488 in saline (minimum specific activity 1000 TBq/mmol by amino acid analysis). Both HESA and LESA Tc-99m-RP488 labeled at > 90% purity. In vitro, HESA Tc-99m-RP488 incubated with streptavidin agarose was bound quantitatively, but there was competition from addition of increasing amounts of cold RP488. In rats, radiotracer uptake was evident at the site of implantation of streptavidin agarose beads for the HESA dose, less uptake of low effective specific activity (LESA) material, and no appreciable uptake in the control rats of the LESA or HESA dose. The target-to-background ratio for HESA Tc-99m-RP488 was 5.4 times that of the control. The solid-phase technology offers a convenient way to prepare high specific activity receptor targeting Tc-99m radiopharmaceuticals. NUCL MED BIOL 27;8:803-807, 2000. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:803 / 807
页数:5
相关论文
共 17 条
[1]  
BABICH JW, 1993, J NUCL MED, V34, P1964
[2]  
Bodanszky M., 1984, PRACTICE PEPTIDE SYN
[3]   PROPERTIES OF STREPTAVIDIN BIOTIN-BINDING PROTEIN PRODUCED BY STREPTOMYCETES [J].
CHAIET, L ;
WOLF, FJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1964, 106 (1-3) :1-&
[4]   Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence [J].
Decristoforo, C ;
Mather, SJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (08) :869-876
[5]  
DIZIO JP, 1992, J NUCL MED, V33, P558
[6]   Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology [J].
Dunn-Dufault, R ;
Pollak, A ;
Thornback, JR ;
Ballinger, JR .
BIOCONJUGATE CHEMISTRY, 1999, 10 (05) :832-837
[7]   THE IN-VIVO USES OF STREPTAVIDIN AND BIOTIN - A SHORT PROGRESS REPORT [J].
HNATOWICH, DJ .
NUCLEAR MEDICINE COMMUNICATIONS, 1994, 15 (08) :575-577
[8]   Validation and application of a solid phase chemistry method for preparation of high effective specific activity technetium-99m radiopharmaceuticals [J].
Kao, CHK ;
Baidoo, KE ;
Lever, SZ .
NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (06) :499-505
[9]   Imaging of dopamine transporters in humans with technetium-99m TRODAT-1 [J].
Kung, HF ;
Kim, HJ ;
Kung, MP ;
Meegalla, SK ;
Plossl, K ;
Lee, HK .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (11) :1527-1530
[10]  
LAMSON ML, 1975, J NUCL MED, V16, P639